Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 653-659

  Takahashi, Toshiaki ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Murakami, Haruyasu ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Dexamethasone; Pharmacokinetics; Substance P

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE SODIUM PHOSPHATE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANISETRON; NAVELBINE; SUBSTANCE P;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; ETHNIC DIFFERENCE; FEMALE; HUMAN; IN VIVO STUDY; JAPANESE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MONOTHERAPY; NAUSEA AND VOMITING; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; IMMUNOENZYME TECHNIQUES; JAPAN; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MORPHOLINES; NAUSEA; SMALL CELL LUNG CARCINOMA; SUBSTANCE P; VOMITING; YOUNG ADULT;

EID: 79959331489     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1519-2     Document Type: Article

References (18)

1. FD Tattersall W Rycroft M Cumberbatch G Mason S Tye DJ Williamson JJ Hale SG Mills PE Finke M MacCoss S Sadowski E Ber M Cascieri RG Hill DE MacIntyre RJ Hargreaves 2000 The novel NK1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets Neuropharmacology 39 652 663 10728886 10.1016/S0028-3908(99)00172-0 1:CAS:528:DC%2BD3cXhtFWqs7w%3D
2. 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials Eur J Cancer 41 1278 1285 15939263 10.1016/j.ejca.2005.01.024 1:CAS:528: DC%2BD2MXltFCktrk%3D
3. DG Warr PJ Hesketh RJ Gralla HB Muss J Herrstedt PD Eisenberg H Raftopoulos SM Grunberg M Gabriel A Rodgers N Bohidar G Klinger CM Hustad KJ Horgan F Skobieranda 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830 15837996 10.1200/JCO.2005.09.050 1:CAS:528:DC%2BD2MXktleqt74%3D
4. MG Kris PJ Hesketh MR Somerfield P Feyer R Clark-Snow JM Koeller GR Morrow LW Chinnery MJ Chesney RJ Gralla SM Grunberg 2006 American society of clinical oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932 2947 16717289 10.1200/JCO.2006.06.9591 1:CAS:528: DC%2BD28XntV2gs7k%3D
5. F Rolia PJ Hesketh J Herrstedt 2006 The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference Ann Oncol 17 20 28 10.1093/annonc/mdj944
6. TM (2007) Antiemesis V.1
7. RA Blum A Majumdar J McCrea J Busillo LH Orlowski D Panebianco M Hesney KJ Petty MR Goldberg MG Murphy KM Gottesdiener CM Hustad C Lates WK Kraft S Van Buren SA Waldman HE Greenberg 2003 Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects Clin Ther 25 1407 1419 12867217 10.1016/S0149-2918(03)80128-5 1:CAS:528:DC%2BD3sXlsFCmtr4%3D
8. AK Shah TL Hunt SC Gallagher MT Cullen Jr. 2005 Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers Curr Med Res Opin 21 595 601 15899109 10.1185/030079905X40481 1:CAS:528:DC%2BD2MXltlWmsL8%3D
9. 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol Ther 74 17 24 12844131 10.1016/S0009-9236(03)00066-3 1:CAS:528: DC%2BD3sXkvFGhsLg%3D
10. S Nakade T Ohno J Kitagawa Y Hashimoto M Katayama H Awata Y Kodama Y Miyata 2008 Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting Cancer Chemother Pharmacol 63 75 83 18317761 10.1007/s00280-008-0713-y 1:CAS:528: DC%2BD1cXhtF2kur%2FJ
11. PJ Hesketh MG Kris SM Grunberg T Beck JD Hainsworth G Harker MS Aapro D Gandara CM Lindley 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109 8996130 1:STN:280: DyaK2s7kvFehsA%3D%3D
12. P Nygren K Hande KJ Petty M Fedgchin K van Dyck A Majumdar D Panebianco M de Smet T Ahmed MG Murphy KM Gottesdiener V Cocquyt S van Belle 2005 Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients Cancer Chemother Pharmacol 55 609 616 15723220 10.1007/s00280-004-0946-3 1:CAS:528:DC%2BD2MXjslOmt7o%3D
13. RI Sanchez RW Wang DJ Newton R Bakhtiar P Lu SH Chiu DC Evans SE Huskey 2004 Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant Drug Metab Dispos 32 1287 1292 15304427 10.1124/dmd.104.000216 1:CAS:528:DC%2BD2cXovFCktbY%3D
14. AK Majumdar L Howard MR Goldberg L Hickey M Constanzer PL Rothenberg TM Crumley D Panebianco TE Bradstreet AJ Bergman SA Waldman HE Greenberg K Butler A Knops I De Lepeleire N Michiels KJ Petty 2006 Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers J Clin Pharmacol 46 291 300 16490805 10.1177/0091270005283467 1:CAS:528:DC%2BD28Xitl2qsbk%3D
15. SP Chawla SM Grunberg RJ Gralla PJ Hesketh C Rittenberg ME Elmer C Schmidt A Taylor AD Carides JK Evans KJ Horgan 2003 Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting Cancer 97 2290 2300 12712486 10.1002/cncr.11320 1:CAS:528:DC%2BD3sXjvVSjsL8%3D
16. P Heitz JM Polak DM Timson AG Pearse 1976 Enterochromaffin cells as the endocrine source of gastrointestinal substance P Histochemistry 49 343 347 791906 10.1007/BF00496138 1:CAS:528:DyaE2sXhsVentg%3D%3D
17. AL Freed KL Audus SM Lunte 2001 Investigation of substance P transport across the blood-brain barrier Peptides 23 157 165 10.1016/S0196-9781(01)00592-7
18. GM Higa ML Auber R Altaha D Piktel S Kurian G Hobbs K Landreth 2006 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy J Oncol Pharm Pract 12 201 209 17156592 10.1177/1078155206072080 1:CAS:528:DC%2BD2sXhvFGrtrk%3D